Abstracts tagged "opioids"

Abstract Number: 1064 • ACR Convergence 2021
Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Private Rheumatology Practice: Patient Outcomes
Jessica Farrell¹, Mitchell Miller², Kelsey Hennig³, Kaitlyn McCarthy⁴, Christ Ange Katche⁵ and Jacqueline Cleary⁶, ¹Albany College of Pharmacy and Health Sciences, Steffens Scleroderma Foundation, Albany, NY, ²Bassett Medical Center, Albany, NY, ³Binghamton University, New Lebanon, NY, ⁴Center for Rheumatology, Albany, NY, ⁵Albany College of Pharmacy & Health Sciences, Guilderland, NY, ⁶Albany College of Pharmacy & Health Sciences, Albany, NY
Background/Purpose: With the evolution of disease modifying anti-rheumatic drugs medications, the need for opioids in the treatment of rheumatic diseases has decreased. However, rheumatology professionals…
Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Alexis Ogdie-Beatty¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵, Steven Hass⁶ and Kaleb Michaud⁷, ¹University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, CA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵Novartis Pharmaceuticals Corporation, Weehawken, NJ, ⁶H.E. Outcomes, LLC, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…
Abstract Number: 215 • 2019 ACR/ARP Annual Meeting
Opioid Treatment Pattern in a Community Based Rheumatology Clinic
Reema Andrade¹, Paula Roe - Prior ², Oanh Doan ² and Julio Ramos ², ¹The Wright Center For Graduate Medical Education, Crofton, MD, ²The Wright Center For Graduate Medical Education, Scranton, PA
Background/Purpose: Rheumatologic pain, especially fibromyalgia, is difficult to treat. While Nonsteroidal anti-inflammatory drugs (NSAIDs) are traditionally prescribed as the first line treatment for fibromyalgia, when…
Abstract Number: 274 • 2019 ACR/ARP Annual Meeting
Participation in the Stanford University Chronic Pain Self-Management Program in a Population with a High Prevalence of Arthritis
Dina Jones¹, Louise Murphy ², Ranjita Misra ¹, Alison Vargovich ³, Dana Guglielmo ⁴, Maura Robinson ¹, Samantha Shawley-Brzoska ¹, Sijin Wen ¹, Megan Burkart ¹ and Richard Vaglienti ¹, ¹West Virginia University, Morgantown, WV, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³University at Buffalo - SUNY, Buffalo, NY, ⁴Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA
Background/Purpose: In 2016, 1 in 5 US adults reported chronic pain (CP). Osteoarthritis and rheumatoid arthritis are top causes of CP. The Stanford University Chronic…
Abstract Number: 354 • 2019 ACR/ARP Annual Meeting
Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Sukhraj Singh¹, Anthony Ocon ¹, Mark Riley ², Jennifer Tchervenkov ¹ and Ruben Peredo-Wende ¹, ¹Albany Medical Center, Albany, NY, ²Albany Medical Center, Albany
Background/Purpose: The Opioid Epidemic has been declared a public health emergency since 2017. The use of opioids in the acute crystal induced arthritis (ACIA) population…
Abstract Number: 910 • 2019 ACR/ARP Annual Meeting
Is There Any Role for Opioids in the Management of OA?
Mikala Osani ¹, Stefan Lohmander ² and Raveendhara Bannuru¹, ¹Tufts Medical Center, Boston, MA, ²Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden, Lund, Sweden
Background/Purpose: Opioids have long been prescribed for chronic pain conditions, including osteoarthritis (OA). Although the safety of opioids has been questioned, there is little information…
Abstract Number: 954 • 2019 ACR/ARP Annual Meeting
Physical Therapy and Opioid Use in Knee Osteoarthritis
Deepak Kumar¹, Christine Peloquin ², Andrew Stokes ³, Lee Marinko ⁴, James Camarinos ⁴, David Felson ⁵ and Maureen Dubreuil ², ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, ³Boston University School of Public Health, Boston, ⁴Boston University, Boston, ⁵Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of chronic pain in older adults. Physical therapy (PT) decreases OA pain and consequently may reduce burden…
Abstract Number: 1097 • 2019 ACR/ARP Annual Meeting
Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
Lingyi Li¹, Na Lu ¹, Jacek Kopec ², John Esdaile ³, Hui Xie ⁴ and J. Antonio Avina-Zubieta ², ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are prescribed for the management of pain among patients with rheumatic diseases including systemic lupus erythematosus (SLE). However,…
Abstract Number: 1129 • 2019 ACR/ARP Annual Meeting
Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Jamie Huizinga¹, Elizabeth Stanley ¹, Shuang Song ¹, James Sullivan ², Jeffrey Katz ³ and Elena Losina ⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital/Harvard Medical School, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Symptomatic knee OA affects 14 million adults in the US. Recent estimates suggest that about 40% of people with knee OA are taking prescription…
Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Janet Pope¹, Yvonne Lee ², Jeffrey Curtis ³, Daojun Mo ⁴, Terence Rooney ⁴, Li Xie ⁴, Christina Dickson ⁴, Douglas Schlichting ⁴, Amanda Quebe ⁴, Anabela Cardoso ⁴, Lee Simon ⁵ and Peter Taylor ⁶, ¹Western University, London, ON, Canada, ²Northwestern University Feinberg School of Medicine, Chicago, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵SDG LLC, Cambridge, MA, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
Abstract Number: 2047 • 2019 ACR/ARP Annual Meeting
Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain
Jasvinder Singh¹ and John Cleveland ², ¹University of Alabama Medical Center, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rates of opioid abuse and associated mortality is a problem of epidemic proportion in the U.S. To our knowledge, limited data are available on…
Abstract Number: 2048 • 2019 ACR/ARP Annual Meeting
Opioid Prescription Use Among Patients with Rheumatic Disease: A Population Based Cohort Study
April Jorge¹, Na Lu ² and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA
Background/Purpose: Rheumatic diseases can be associated with pain and disability. An international opioid epidemic is ongoing, and prescription opioid use has been linked with increased…
Abstract Number: 2076 • 2019 ACR/ARP Annual Meeting
The Opioid Epidemic: The Rheumatology Response to Management of Chronic Pain
Michael Grant¹, Alysia Kwiatkowski ¹ and Najia Shakoor ¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: Pain is the hallmark symptom of many rheumatologic conditions and chronic pain management is a major part of clinical practice in rheumatology. Therefore, as…
Abstract Number: 2553 • 2019 ACR/ARP Annual Meeting
Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Emily Somers¹, Sioban Harlow ¹, Nina Zhou ¹, Lu Wang ¹, Kamil Barbour ², Charles Helmick ³, Caroline Gordon ⁴, Deeba Minhas ¹, Beth Wallace ¹, Afton Hassett ¹, Suzanna Zick ¹, W. Joseph McCune ⁵ and Wendy Marder ¹, ¹University of Michigan, Ann Arbor, ²Centers for Disease Control and Prevention, Atlanta, ³Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: We recently reported prescription opioid use in nearly one-third of systemic lupus erythematosus (SLE) patients in our population-based cohort. Data suggest that opioids may…
Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting
Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Dale Seguin¹, Christine Peschken ², Casandra Dolovich ¹, Ruby Grymonpre ¹, Phil St. John ¹ and Annaliese Tisseverasinghe ¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds), is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].